Men with premature ejaculation who used the UK biotechnology firm Plethora Solutions' PSD502 (lidocaine/prilocaine) topical spray five minutes before intercourse were able to delay their orgasm six times longer than normal, according to a study published in the journal BJU International.
300 men took part in the Phase III, multicenter, double-blind, randomized study. The time from penetration to ejaculation increased from an average of 0.6 minutes to 3.8 minutes in the medicated group and to just 1.1 minutes in the placebo cohort.
90% of the men in the treatment arm were able to delay ejaculation for more than one minute, compared with 54% in the placebo group. 74% of men using PSD502 managed to last more than two minutes, compared with 22% for placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze